Supplementary documents

netCRS: Network-based comorbidity risk score for prediction of myocardial infarction using biobank-scaled PheWAS data

Yonghyun Nam^{1,§}, Sang-Hyuk Jung^{1,2,§}, Anurag Verma³, Vivek Sriram¹, Hong-Hee Won², Jae-Seung Yun^{1,4}, Regeneron Genetics Center, and Dokyoon Kim^{1,5,*}

*Corresponding author: Dokyoon Kim, PhD

Department of Biostatistics, Epidemiology & Informatics, The Perelman School of Medicine, University of Pennsylvania, B304 Richards Building, 3700 Hamilton Walk, University of Pennsylvania, Philadelphia, PA 19104-6116, United States.

Tel.: +1-215-573-5336; Fax: +1-215-573-3111; E-mail: dokyoon.kim@pennmedicine.upenn.edu

¹Department of Biostatistics, Epidemiology & Informatics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

²Samsung Advanced Institute for Health Sciences and Technology (SAIHST), Sungkyunkwan University, Samsung Medical Center, Seoul 06351, Republic of Korea

³Department of Genetics, Perelman School of Medicine, University of Pennsylvania, Philadelphia, PA 19104, USA

⁴Division of Endocrinology and Metabolism, Department of Internal Medicine, St. Vincent's Hospital, College of Medicine, The Catholic University of Korea, Seoul 06591, Republic of Korea

⁵Institute for Biomedical Informatics, University of Pennsylvania, Philadelphia, PA 19104, USA

[§]Y.Nam and S-H.Jung equally contributed for co-first author

^{© 2021} The Authors. Open Access chapter published by World Scientific Publishing Company and distributed under the terms of the Creative Commons Attribution Non-Commercial (CC BY-NC) 4.0 License.

Supplementary Figure 1. Pseudo-code for netCRS of section 2.2

INPUT:

1. Similarity matrix for DS-Net

Disease-layer ($W_{Disease}$), SNP-layer (W_{SNP}), Disease-SNP association (C)

2. Initialization

 y_{SNP} : Set of initial label vector for SNP-layer, $f_{Disease}$: Set of resulting candidate comorbidity scores N: The number of participants, z: outcome vector for index disease of interest (case: 1 / control: 0)

3. Hyper-parameter

 μ : Hyper-parameter for graph-based SSL

PROCEDURE:

Calculating graph Laplacian matrix for disease-layer

 $\mathbf{L}_{\mathrm{Disease}} = \mathbf{D}_{\mathrm{Disease}} - \mathbf{W}_{\mathrm{Disease}}$, where \mathbf{D} is diagonal degree matrix of \mathbf{W}

$$\underline{For} i = 1:N,$$

Initializing labels for SNP-layer:
$$\mathbf{y}_{\text{SNP}} = (y_1, ..., y_k)^{\text{T}}$$
, where $y_i = \begin{cases} 0 & \text{if genotype CC} \\ 0.5 & \text{if genotype CT} \\ 1 & \text{if genotype TT} \end{cases}$
Applying closed form solution of SSL in Eq. (6): $\mathbf{f}_{\text{Disease}} = \mu(\mathbf{I} + \mu \mathbf{L}_{\text{Disease}})^{-1} \mathbf{C} \cdot \mathbf{y}_{SNP}$

End for

Aggregating predicted scores for netCRS() – Logistic model: \mathbf{z} (MI case vs. Normal control) ~ $\mathbf{f}_{\text{Disease}}$

OUTPUT:

Individual comorbidity risk scores: netCRS() = $\widehat{\boldsymbol{\beta}} \boldsymbol{f}_{\text{Disease}}$

Supplementary Table 1. A list of phenotypes in disease-layer

No.	PheCode Phenotype description		Phenotype category		
1	172	Skin cancer	neoplasms		
2	172.2	Other non-epithelial cancer of skin	neoplasms		
3	174	Breast cancer	neoplasms		
4	198	Secondary malignant neoplasm	neoplasms		
5	198.1	Secondary malignancy of lymph nodes	neoplasms		
6	208	Benign neoplasm of colon	neoplasms		
7	214	Lipoma	neoplasms		
8	214.1	Lipoma of skin and subcutaneous tissue	neoplasms		
9	242	Thyrotoxicosis with or without goiter	endocrine/metabolic		
10	244	Hypothyroidism	endocrine/metabolic		
11	244.1	Secondary hypothyroidism	endocrine/metabolic		
12	244.4	Hypothyroidism NOS	endocrine/metabolic		
13	250.1	Type 1 diabetes	endocrine/metabolic		
14	250.2	Type 2 diabetes	endocrine/metabolic		
15	250.23	Type 2 diabetes with ophthalmic manifestations	endocrine/metabolic		
16	250.7	Diabetic retinopathy	endocrine/metabolic		
17	272	Disorders of lipoid metabolism	endocrine/metabolic		
18	272.1	Hyperlipidemia	endocrine/metabolic		
19	272.11	Hypercholesterolemia	endocrine/metabolic		
20	275	Disorders of mineral metabolism endocrine/metabolism			

21	278	Overweight, obesity and other hyperalimentation	endocrine/metabolic		
22	281	Other deficiency anemia	hematopoietic		
23	281.1	Megaloblastic anemia	hematopoietic		
24	287	Purpura and other hemorrhagic conditions	hematopoietic		
25	287.3	Thrombocytopenia	hematopoietic		
26	290	Delirium dementia and amnestic and other cognitive disorders	mental disorders		
27	292	Neurological disorders	mental disorders		
28	292.4	Altered mental status	mental disorders		
29	296	Mood disorders	mental disorders		
30	296.2	Depression	mental disorders		
31	306	Other mental disorder	mental disorders		
32	318	Tobacco use disorder	mental disorders		
33	331	Other cerebral degenerations	neurological		
34	332	Parkinson's disease	neurological		
35	335	Multiple sclerosis	neurological		
36	365	Glaucoma	sense organs		
37	365.1	Open-angle glaucoma	sense organs		
38	365.11	Primary open angle glaucoma	sense organs		
39	366	Cataract	sense organs		
40	366.2	Senile cataract	sense organs		
41	386.9	Dizziness and giddiness (Light-headedness and vertigo)	sense organs		
42	394.3	Aortic valve disease	circulatory system		
43	395.6	Heart valve replaced	circulatory system		
44	401.1	Essential hypertension	circulatory system		
45	411.1	Unstable angina (intermediate coronary syndrome)	circulatory system		
46	411.2	Myocardial infarction	circulatory system		
47	411.3	Angina pectoris	circulatory system		
48	411.4	Coronary atherosclerosis	circulatory system		
49	411.8	Other chronic ischemic heart disease, unspecified	circulatory system		
50	411.9	Other acute and subacute forms of ischemic heart disease	circulatory system		
51	415	Pulmonary heart disease	circulatory system		
52	418	Nonspecific chest pain	circulatory system		
53	418.1	Precordial pain	circulatory system		
54	426	Cardiac conduction disorders	circulatory system		
55	426.3	Bundle branch block	circulatory system		
56	426.9	Cardiac pacemakerdevice in situ	circulatory system		
57	426.91	Cardiac pacemaker in situ	circulatory system		
58	427	Cardiac dysrhythmias	circulatory system		
59	427.2	Atrial fibrillation and flutter	circulatory system		
60	428	Congestive heart failure; nonhypertensive	circulatory system		
61	428.2	Heart failure NOS	circulatory system		
62	433	Cerebrovascular disease	circulatory system		

63	433.1	Occlusion and stenosis of precerebral arteries	circulatory system	
64	433.21	Cerebral artery occlusion, with cerebral infarction	circulatory system	
65	433.3	Cerebral ischemia	circulatory system	
66	440	Atherosclerosis	circulatory system	
67	442	Other aneurysm	circulatory system	
68	442.1	Aortic aneurysm	circulatory system	
69	443	Peripheral vascular disease	circulatory system	
70	443.9	Peripheral vascular disease, unspecified	circulatory system	
71	447	Other disorders of arteries and arterioles	circulatory system	
72	451	Phlebitis and thrombophlebitis	circulatory system	
73	451.2	Phlebitis and thrombophlebitis of lower extremities	circulatory system	
74	454	Varicose veins	circulatory system	
75	454.1	Varicose veins of lower extremity	circulatory system	
76	455	Hemorrhoids	circulatory system	
77	459	Other disorders of circulatory system	circulatory system	
78	459.9	Circulatory disease NEC	circulatory system	
79	475	Chronic sinusitis	respiratory	
80	480.11	Pneumococcal pneumonia	respiratory	
81	495	Asthma	respiratory	
82	496	Chronic airway obstruction	respiratory	
83	496.1	Emphysema	respiratory	
84	496.2	Chronic bronchitis	respiratory	
85	506	Empyema and pneumothorax	respiratory	
86	507	Pleurisy; pleural effusion	respiratory	
87	509.2	Respiratory insufficiency	respiratory	
88	530	Diseases of esophagus	digestive	
89	530.1	Esophagitis, GERD and related diseases	digestive	
90	535	Gastritis and duodenitis	digestive	
91	535.6	Duodenitis	digestive	
92	550.2	Diaphragmatic hernia	digestive	
93	557	Intestinal malabsorption (non-celiac)	digestive	
94	557.1	Celiac disease	digestive	
95	562	Diverticulosis and diverticulitis	digestive	
96	562.1	Diverticulosis	digestive	
97	564	Functional digestive disorders	digestive	
98	564.9	Personal history of diseases of digestive system	digestive	
99	565	Anal and rectal conditions	digestive	
100	565.1	Anal and rectal polyp	digestive	
101	569	Other disorders of intestine	digestive	
102	571	Chronic liver disease and cirrhosis	digestive	
103	571.5	Other chronic nonalcoholic liver disease	digestive	

105	574.1	Cholelithiasis	digestive		
106	574.11	Cholelithiasis with acute cholecystitis	digestive		
107	574.12	Cholelithiasis with other cholecystitis	digestive		
108	574.2	Calculus of bile duct	digestive		
109	574.3	Cholecystitis without cholelithiasis	digestive		
110	575	Other biliary tract disease	digestive		
111	575.7	Other disorders of gallbladder	digestive		
112	579	Other symptoms involving abdomen and pelvis	digestive		
113	586	Other disorders of the kidney and ureters	genitourinary		
114	593	Hematuria	genitourinary		
115	594	Urinary calculus	genitourinary		
116	596	Other disorders of bladder	genitourinary		
117	599	Other symptomsdisorders or the urinary system	genitourinary		
118	686.1	Carbuncle and furuncle	dermatologic		
119	696	Psoriasis and related disorders	dermatologic		
120	696.4	Psoriasis	dermatologic		
121	696.41	Psoriasis vulgaris	dermatologic		
122	704	Diseases of hair and hair follicles	dermatologic		
123	706	Diseases of sebaceous glands	dermatologic		
124	706.2	Sebaceous cyst	dermatologic		
125	714	Rheumatoid arthritis and other inflammatory polyarthropathies	musculoskeletal		
126	714.1	Rheumatoid arthritis	musculoskeletal		
127	716	Other arthropathies	musculoskeletal		
128	716.9	Arthropathy NOS	musculoskeletal		
129	728.71	Contracture of palmar fascia [Dupuytren's disease]	musculoskeletal		
130	735.2	Acquired toe deformities	musculoskeletal		
131	742	Derangement of joint, non-traumatic	musculoskeletal		
132	743	Osteoporosis, osteopenia and pathological fracture	musculoskeletal		
133	747	Cardiac and circulatory congenital anomalies	congenital anomalies		
134	747.1	Cardiac congenital anomalies	congenital anomalies		
135	747.13	Congenital anomalies of great vessels	congenital anomalies		

Supplementary Table 2. Nagelkerke's R^2 values of PRS in the classification of myocardial infarction cases and controls at the linkage disequilibrium clumping and p-value thresholds

LD -clump r^2	<i>p</i> -value	Nagelkerke's R ²	<i>p</i> -value	Beta	Standard	Number o
threshold	threshold	8	1		error	used SNP
	5.00E-08	0.0093	8.00E-14	0.5414	0.0725	32
	1.00E-06	0.0085	8.53E-13	0.4108	0.0574	63
>0.1	0.0001	0.0111	3.52E-16	0.2882	0.0353	307
***	0.001	0.0111	4.30E-16	0.1609	0.0198	1483
	0.01	0.0099	1.52E-14	0.0708	0.0092	9685
	0.05	0.0085	9.78E-13	0.0366	0.0051	37482
	5.00E-08	0.0071	6.30E-11	0.3831	0.0586	39
	1.00E-06	0.0070	9.55E-11	0.3143	0.0485	73
>0.2	0.0001	0.0095	5.07E-14	0.2287	0.0304	348
	0.001	0.0110	5.66E-16	0.1418	0.0175	1638
	0.01	0.0116	9.44E-17	0.0678	0.0082	10863
	0.05	0.0103	4.74E-15	0.0348	0.0044	44067
	5.00E-08	0.0070	9.82E-11	0.3126	0.0483	45
	1.00E-06	0.0075	2.31E-11	0.2684	0.0401	85
>0.3	0.0001	0.0103	4.42E-15	0.2024	0.0258	388
	0.001	0.0117	7.15E-17	0.1274	0.0153	1805
	0.01	0.0130	1.58E-18	0.0640	0.0073	11911
	0.05	0.0111	4.27E-16	0.0316	0.0039	49675
	5.00E-08	0.0063	7.37E-10	0.2552	0.0414	50
	1.00E-06	0.0065	4.72E-10	0.2072	0.0333	99
>0.4	0.0001	0.0093	1.03E-13	0.1647	0.0221	438
	0.001	0.0115	1.15E-16	0.1123	0.0136	1962
	0.01	0.0144	2.51E-20	0.0603	0.0065	12985
	0.05	0.0121	2.38E-17	0.0292	0.0034	55003
	5.00E-08	0.0061	1.84E-09	0.2139	0.0356	56
	1.00E-06	0.0063	7.36E-10	0.1746	0.0283	113
>0.5	0.0001	0.0088	4.52E-13	0.1361	0.0188	492
0.0	0.001	0.0118	5.29E-17	0.1006	0.0120	2133
	0.01	0.0153	1.42E-21	0.0557	0.0058	14160
	0.05	0.0128	2.60E-18	0.0267	0.0031	60663
	5.00E-08	0.0057	6.01E-09	0.1700	0.0292	67
	1.00E-06	0.0064	6.34E-10	0.1549	0.0251	124
>0.6	0.0001	0.0092	1.23E-13	0.1202	0.0162	561
0.0	0.001	0.0121	1.99E-17	0.0888	0.0105	2353
	0.01	0.0162	1.05E-22	0.0506	0.0052	15489
	0.05	0.0134	4.72E-19	0.0240	0.0027	66890
	5.00E-08	0.0059	3.34E-09	0.1499	0.0253	76
	1.00E-06	0.0062	1.30E-09	0.1265	0.0208	146
>0.7	0.0001	0.0089	3.51E-13	0.0990	0.0136	631
	0.001	0.0118	5.97E-17	0.0733	0.0088	2650
	0.01	0.0170	9.14E-24	0.0447	0.0044	17122
	0.05	0.0148	6.25E-21	0.0219	0.0023	74227
	5.00E-08	0.0049	7.42E-08	0.0839	0.0156	100
	1.00E-06	0.0055	8.75E-09	0.0791	0.0138	188
>0.8	0.0001	0.0084	1.37E-12	0.0702	0.0099	757 2042
	0.001	0.0124	8.29E-18	0.0592	0.0069	3042
	0.01	0.0170	8.31E-24	0.0377	0.0057	19321
	0.05	0.0160	2.19E-22	0.0191	0.0020	84126
	5.00E-08	0.0036	3.72E-06	0.0454	0.0098	135
	1.00E-06	0.0046	1.50E-07	0.0472	0.0090	247
>0.9	0.0001	0.0071	6.79E-11	0.0448	0.0069	969
	0.001 0.01	0.0112 0.0171	3.59E-16	0.0406	0.0050	3747
		Λ Λ1 71	7.40E-24	0.0282	0.0028	23106

Supplementary Table 3. Demographics of participants according to netCRS risk groups

net	CRS	Low	Intermediate	High	Very high	P-value
Number of sa	mples	(n=1243)	(n=1243)	(n=1243)	(n=1243)	
Age		61.7 ± 15.2	61.8 ± 15.2	62.0 ± 14.7	62.6 ± 14.3	0.116
Sex	Female (%)	778 (62.6%)	771 (62.0%)	769 (61.9%)	800 (64.4%)	0.539
Myocardial infarction	Cases (%)	94 (7.6%)	150 (12.1%)	218 (17.5%)	301 (24.20%)	< 0.001
	Controls (%)	1149 (92.4%)	1093 (87.9%)	1025 (82.5%)	942 (75.80%)	